Renal cell carcinoma · line 1 · Nivolumab + cabozantinib (RCC, 1L)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-NIVO-CABO-RCC |
| ID | IND-RCC-METASTATIC-1L-NIVO-CABO |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-03 | pending_clinical_signoff |
| Diseases | DIS-RCC |
| Sources | SRC-CHECKMATE-9ER-CHOUEIRI-2021 SRC-ESMO-RCC-2024 SRC-NCCN-KIDNEY-2025 |
Notes
Nivo+cabo provides balanced ICI+TKI combination with good tolerability profile relative to lenv+pembro. Especially preferred in patients with bone metastases (cabozantinib MET/AXL inhibition), ECOG 1-2 patients where lenvatinib hypertension is a concern, or where simpler dosing schedule is preferred.
Used By
Algorithms
ALGO-RCC-METASTATIC-1L- ALGO-RCC-METASTATIC-1L